免疫治疗长期生存者:毒性、体成分与健康相关生活质量评估
该研究评估了217例接受抗PD-1/PD-L1治疗且生存超过2年的黑色素瘤、肾细胞癌或非小细胞肺癌患者,发现慢性免疫相关不良事件(如甲状腺功能减退10.6%)较常见,但未观察到明确的心脏代谢不良影响,患者报告的生活质量结局良好。
要点
- 长期生存者中慢性免疫相关不良事件常见,甲状腺功能减退发生率为10.6%。
- 治疗开始后两年内血压、血糖和BMI无显著变化,但体成分显示脂肪增加。
- 患者报告的生活质量结局优于癌症和一般人群,但年轻和需后续治疗者更差。
核心结论
- 抗PD-1/PD-L1治疗可产生持久反应且健康相关生活质量结局良好。
- 慢性事件可能比先前认为的更常见,但未观察到明确的心脏代谢不良影响。
研究设计与样本
- 研究评估了2009年至2017年间接受抗PD-1/PD-L1治疗的217例黑色素瘤、肾细胞癌或非小细胞肺癌患者,且治疗结束后生存超过两年。
- 追踪患者和肿瘤特征、免疫相关不良事件、心脏代谢参数、体成分和健康相关生活质量结局。
主要发现
- 大多数患者为男性(70.3%),开始治疗时平均年龄61.0岁,中位BMI为28.5。
- 中位总生存未达到,随访期间33例(15.2%)死亡,主要死于癌症进展(n=28)。
- 末次随访时,大多数患者ECOG体能状态为0(38%)或1(41%)。
- 从基线至治疗开始后两年,血压、血糖或BMI无差异。
- 体成分显示脂肪增加(p=0.05)、骨骼肌质量增加(p=0.03)和骨骼肌指数增加(p=0.04)。
临床怎么用
- 对接受抗PD-1/PD-L1治疗的长期生存者,应监测慢性免疫相关不良事件如甲状腺功能减退、关节炎等。
- 尽管未观察到明确心脏代谢不良影响,仍需关注体成分变化如脂肪增加。
- 年轻患者和需要后续治疗的患者可能生活质量更差,需针对性支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Antibodies to programmed death-1 receptor and its ligand (anti-PD-1/PD-L1) produce durable responses in many cancers. However, the long-term effects of anti-PD-1/PD-L1 blockade are not well defined. We identified the toxicities, health outcomes and health-related quality of life (HRQoL) amongst long-term survivors treated with anti-PD-1/PD-L1. METHODS: We assessed 217 patients who received anti-PD-1/PD-L1 for melanoma, renal cell carcinoma or non-small-cell lung carcinoma between 2009 and 2017, with survival greater than two years after treatment. Patient and tumour characteristics, immune-related adverse events (irAEs), cardiometabolic parameters (glucose, blood pressure, body mass index [BMI]), body composition (using automated body composition analyser, computed tomography and Slice-o-matic software) and HRQoL outcomes were tracked. RESULTS: Among the included patients, most were men (70.3%) and at anti-PD-1/PD-L1 initiation had an average age of 61.0 years and median BMI of 28.5. Median overall survival was not reached; 33 (15.2%) died during the follow-up primarily from progressive cancer (n = 28). At the last follow-up, most patients' Eastern Cooperative Oncology Group performance status was 0 (38%) or 1 (41%). There was no difference in blood pressure, glucose or BMI from baseline to two years after treatment initiation. Body composition showed increased adiposity (p = 0.05), skeletal muscle mass (p = 0.03) and skeletal muscle gauge (p = 0.04). We observed chronic irAEs at the last follow-up including hypothyroidism (10.6%), arthritis (3.2%), adrenal insufficiency (3.2%) and neuropathy (2.8%). New diagnoses of type 2 diabetes (6.5%) and hypertension (6.0%) were observed, with uncertain relationship to anti-PD-1/PD-L1. Patient-reported outcomes compared favourably with cancer and general populations, although younger age (p = 0.003) and need for subsequent therapy (p = 0.03) were associated with worse HRQoL outcomes. CONCLUSION: Durable responses to anti-PD-1/PD-L1 therapy and favourable HRQoL outcomes are encouraging. Chronic events may be more common than previously thought although no clear chronic adverse cardiometabolic effects were observed.
引用
- Patrinely JR, Young AC, Quach H, et al. Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand. Eur J Cancer. 2020. PMID: 32599411. doi:10.1016/j.ejca.2020.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。